Pamalican Asset Management Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Pamalican Asset Management Ltd bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the company's stock, valued at approximately $1,338,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JANX. Janus Henderson Group PLC raised its position in shares of Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock valued at $114,587,000 after buying an additional 721,563 shares in the last quarter. Vanguard Group Inc. increased its stake in Janux Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock worth $114,379,000 after acquiring an additional 288,402 shares during the last quarter. Geode Capital Management LLC raised its position in Janux Therapeutics by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock valued at $38,288,000 after purchasing an additional 52,362 shares during the period. Wellington Management Group LLP lifted its stake in shares of Janux Therapeutics by 3,592.9% in the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock valued at $28,665,000 after purchasing an additional 520,898 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Janux Therapeutics by 2,519.6% in the 4th quarter. Franklin Resources Inc. now owns 497,287 shares of the company's stock worth $26,625,000 after purchasing an additional 478,304 shares during the period. 75.39% of the stock is owned by institutional investors.

Remove Ads

Janux Therapeutics Stock Performance

JANX traded down $1.39 during trading on Monday, hitting $24.38. 1,871,078 shares of the stock were exchanged, compared to its average volume of 856,612. The firm has a 50 day simple moving average of $34.09 and a 200 day simple moving average of $45.24. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -20.84 and a beta of 3.27. Janux Therapeutics, Inc. has a 1 year low of $23.40 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on JANX shares. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Scotiabank dropped their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush restated an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $92.44.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 11,668 shares of company stock worth $548,183 over the last 90 days. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.